foci < focus < focused

Facettes : Author.f AffPays.f AffOrg.f AffRegion.f AffVille.f

List of bibliographic references

Number of relevant bibliographic references: 25.
[0-20] [0 - 20][0 - 25][20-24][20-40]

Ident.	Authors (with country if any)	Title
000125 (2012)	Nicolas Rohleder [États-Unis] ; Martin Aringer [Allemagne] ; Matthias Boentert [Allemagne]	Role of interleukin‐6 in stress, sleep, and fatigue
000144 (2012)	U. Lange [Allemagne] ; U. Müller-Ladner [Allemagne]	Potenzielle rheumatologische Medikamentenwechselwirkungen im Alter
000160 (2011)	Susumu Nishiyama [Japon] ; Tetsushi Aita [Japon] ; Yasuhiko Yoshinaga [Japon] ; Hiroki Kishimoto [Japon] ; Michio Toda [Japon] ; Yoshiki Yoshihara [Japon] ; Shinya Miyoshi [Japon] ; Akira Manki [Japon] ; Shoji Miyawaki [Japon]	Proposing a method of regional assessment and a novel outcome measure in rheumatoid arthritis
000181 (2015)	Yi Zhang [États-Unis] ; Xiaohui Wei [États-Unis] ; Gaurav Bajaj [États-Unis] ; Jeffrey S. Barrett [États-Unis] ; Bernd Meibohm [États-Unis] ; Amita Joshi [États-Unis] ; Manish Gupta [États-Unis]	Challenges and considerations for development of therapeutic proteins in pediatric patients
000247 (2011)	Bruce H. Littman [États-Unis]	An NIH National Center for Advancing Translational Sciences: is a focus on drug discovery the best option?
000306 (2013)	Pavel Horák [République tchèque] ; Martina Skácelová [République tchèque] ; Karel Hejduk [République tchèque] ; Andrea Smržová [République tchèque] ; Karel Pavelka [République tchèque]	Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic—data from the ATTRA registry
000420 (2010)	S. Pankuweit [Allemagne] ; B. Maisch [Allemagne]	Das Herz bei viralen Infektionen
000533 (2009)	E. Choy [Royaume-Uni] ; N. Sattar [Royaume-Uni]	Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions
000535 (2013)	Oliver Foot ; Anshuman Malaviya	Treatment of rheumatoid arthritis: current and future
000821 (2013)	R. Kessel [États-Unis] ; C. Hu [États-Unis] ; L. Shore-Lesserson [États-Unis] ; J. Rand [États-Unis] ; D. Manwani [États-Unis]	A child with acquired factor XIII deficiency: case report and literature review
000925 (2012)	P. A. Laires [Portugal] ; F. Exposto [Portugal] ; R. Mesquita [Portugal] ; A. P. Martins [Portugal] ; L. Cunha-Miranda [Portugal] ; J. E. Fonseca [Portugal]	Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries
000958 (2009)	Ewa M. Paleolog [Royaume-Uni]	The vasculature in rheumatoid arthritis: cause or consequence?
000959 (2012)	Mindy S. Lo [États-Unis] ; George C. Tsokos [États-Unis]	Treatment of systemic lupus erythematosus: new advances in targeted therapy
000A50 (2011)	Jisna R. Paul [États-Unis] ; Prabha Ranganathan [États-Unis]	Clinical trials in rheumatoid arthritis: a status report from the ClinicalTrials.gov website
000B29 (2010)	W. Fiori [Allemagne] ; A. Liedtke-Dyong [Allemagne] ; H.-J. Lakomek [Allemagne] ; K. Buscham [Allemagne] ; H. Lehmann [Allemagne] ; W. Liman [Allemagne] ; A.-K. Fuchs [Allemagne] ; F. Bessler [Allemagne] ; N. Roeder [Allemagne]	Das G-DRG-System 2010 – Relevantes für die Rheumatologie
000B97 (2015)	Zhenhua Xu [États-Unis] ; Hugh M. Davis [États-Unis] ; Honghui Zhou [États-Unis]	Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety
000C81 (2006)	Marcello Maggio [États-Unis] ; Jack M. Guralnik [États-Unis] ; Dan L. Longo [États-Unis] ; Luigi Ferrucci [États-Unis]	Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway
000E13 (2013)	M. Stergaard [Danemark]	SP0059 What is new: Clinical implications of imaging advances
000E80 (2006)	Burkhard Möller [Suisse] ; Peter M. Villiger [Suisse]	Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases
000F71 (2016)	Erkan Alpsoy [Turquie]	Behçet's disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions
001210 (2012)	B. F. Ricciardi [États-Unis] ; J. Paul [États-Unis] ; A. Kim [États-Unis] ; L. A. Russell [États-Unis] ; J. M. Lane [États-Unis]	Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "focus" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "focus" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    focus
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021